Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Corticosteroid Versus Placebo Injection in Patients With Syndesmotic Ligament Injury or High Ankle Sprain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 16 years or older~* Musculoskeletal ultrasound performed which demonstrates injury pattern consistent with high ankle sprain.~* Must sign the informed consent form and agree to meet the needs of the study~* Clinically and ultra sound confirmed and isolated syndesmotic ligament injury or high ankle sprain without associated fracture~* Injury occurred within the previous 7 days~Exclusion Criteria:~* Surgical intervention required to stabilize the ankle~* Unable to read and understand the consent form~* Unable to meet the needs of the follow-up examinations~* Allergic to the betamethasone~* Current fungal infection~* Pregnancy or currently breast feeding

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bupivacaine hydrochloride and betamethasone sodium phosphate (Type: EXPERIMENTAL): When the patient has been randomized to either group, a licensed provider under the direction of the PI, will utilize the ultrasound to identify the inferior tibiofibular ligament (syndesmotic ligament). This provider that performs the injection will not be involved in any follow-up visits or return to play review. When appropriate positioning is confirmed the area will be injected with a mixture of 5 ml of 0.25 % bupivacaine hydrochloride and 2 ml of 3 mg/ml betamethasone sodium phosphate (Celestone® Soluspan®) (BTM)
- bupivacaine hydrochloride (Type: ACTIVE_COMPARATOR): When the patient has been randomized to either group, a licensed provider under the direction of the PI, will utilize the ultrasound to identify the inferior tibiofibular ligament (syndesmotic ligament). This provider that performs the injection will not be involved in any follow-up visits or return to play review. When appropriate positioning is confirmed, the area will be injected with 5ml of bupivacaine hydrochloride.

Based on this trial design, predict the completion outcome and termination type (if applicable).